Seagen
About
Seagen is dedicated to improving patient outcomes with advanced antibody-drug conjugate technology.
- Bothell,Washington,United States
- 1001 - 5000
- https://www.seagen.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $1B
- Industries
- Biotechnology,Health Care,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 1998
- Number Of Employee
- 1001 - 5000
- Operating Status
- Active
- Stock Symbol
- nasdaq:SGEN
- Legal Name
- Seattle Genetics, Inc.
- Also Known As
- Seattle Genetics
Seattle Genetics is a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 14, 2020 | Post-IPO Equity | $1B | 1 |
Merck
|
— | Detail |
| Jul 26, 2019 | Post-IPO Equity | $575M | — | — | — | Detail |
| Jan 17, 2014 | Post-IPO Equity | $9M | 1 | — | — | Detail |
| Feb 2, 2011 | Post-IPO Equity | $155M | — | — | — | Detail |
| Jan 1, 2009 | Post-IPO Equity | — | 1 | — | — | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Jun 11, 2015
Cogent Biosciences
|
Series B | $65M | Biotechnology | — |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Merck
|
Yes | Post-IPO Equity |
Takeda
|
— | Post-IPO Equity |
New Enterprise Associates
|
— | Post-IPO Equity |
Sofinnova Investments
|
— | Series Unknown |
Employee Profiles
Exits
Seagen has had 2 exits. Seagen most notable exits include Cogent Biosciences , Pieris Pharmaceuticals
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Mar 29, 2018 | Cogent Biosciences | IPO | Biotechnology | Detail |
| Jan 9, 2015 | Pieris Pharmaceuticals | IPO | Biopharma | Detail |
Acquisition
Seagen has acquired 1 organizations. Their most recent acquisition was Cascadian Therapeutics on Jan 31, 2018. They acquired Cascadian Therapeutics for $614M.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Jan 31, 2018
Cascadian Therapeutics
|
Biotechnology | acquisition | $ 614M | Detail |
